CTTH 最新10-Q变化
将 CTTH 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2015-11-23 与上一份 10-Q · 2015-08-19
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +10 | −20 | ~1 | 3 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 4 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 3 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2015-11-23
Our wholly owned subsidiary CTT Pharmaceutical Holdings (“CTT”) specializes in drug delivery systems technology within the pharmaceutical industry. CTT Pharma’s focus is fast dissolving drug delivery systems. The company’s revolutionary technology platform includes the development of advanced oral d…
The wafer is an orally administrable paper-thin polymer films used as a carrier for pharmaceutical agents. The wafer rapidly dissolves to release the pharmaceutical agent as soon as it comes in contact with saliva, thus obviating the need for water during administration. This attribute makes the waf…
For the three and nine months ended September 30, 2015 and 2014
For the three months and nine months ended September 30, 2015, we incurred a Net Loss of $(290,864) and $(990,572). This compares with a Net Loss of $(43,196) and $(11,424) for the comparable periods in 2014. The primary reason for the significant increase in our operating losses from 2014 to $2015 …
Foreign currency translations for all periods covered by this report were nominal.
相对上期删除的文字 · 来源:10-Q · 2015-08-19
CTT Pharmaceutical Holdings, Inc. (“CTT Pharmaceutical” or "the Company"), a Delaware Corporation, was incorporated on November 6, 1996 under the name Winchester Mining Corp. The name of the Company was changed to PNW Capital, Inc. on May 16, 2000. In 2002, PNW Capital, Inc. acquired Industrial Mine…
On September 9, 2014 the Company entered into a Share Exchange Agreement with CTT Pharmaceuticals, Inc. (“CTT Pharma”), and its then existing shareholders. As a result of this transaction, CTT Pharma became a wholly owned subsidiary of the Company. Our operations are conducted through CTT Pharma. On…
CTT Pharma specializes in drug delivery systems technology within the pharmaceutical industry. CTT Pharma’s focus is fast dissolving drug delivery systems. The company’s revolutionary technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or …
The Wafer is an orally administrable wafer comprising at least one physiologically acceptable film forming agent. The wafer is formed by mixing the film-forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles. The wafer formulation relat…
The wafer is treated with a pharmaceutical agent designed to reduce or treat a medical condition.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议